

# Ethics in Research & Navigating the IRB Process

Jacque Van Audenhove, MS, CIP

Cindy Langley, RN, CIP

for

Faculty Development

April 13, 2021



# Navigating the IRB & Ethics in Research - Introduction

The IRB has an “open door” policy, (currently a remote door) signifying our willingness to assist & answer questions. We will set up a Zoom/Teams session to walk you through a submission or discuss projects at any point.

Jacque Van Audenhove, MS, CIP

IRB Director

865.368.1022 (cell)/ 865.305.9781 (w)

[jvanaudenhove@utmck.edu](mailto:jvanaudenhove@utmck.edu)

Cindy Langley, RN, CIP

IRB Regulatory Specialist

865.405.8248 (cell)/865.305.6892 (w)

[clangley@utmck.edu](mailto:clangley@utmck.edu)

## Learning Objectives

- Give examples of unethical historical research which led to IRB oversight for clinical research
- Determine the category of IRB review based on risk to subjects
- Know how to complete an IRB application in iMedRIS
- Avoid common pitfalls that may delay IRB approval
- Know who to call when you have questions or need assistance

# Ethics in Research – Historical Perspective

- 1900 WALTER REED YELLOW FEVER STUDY** – [SUBJECTS DELIBERATELY INFECTED - 3 DIED]
- 1932—1973 TUSKEGEE STUDY** - [NONE OFFERED PENICILLIN DEEMED EFFECTIVE IN 1943 - STUDY CONTIUED TO 1973 ]
- 1939 STUTTERING STUDY** [ORPHAN CHILDREN WERE SUBJECTED TO HARRASSMENT IN AN ATTEMPT TO GET THEM TO STUTTER]
- 1946 NAZI DOCTORS' TRIAL** [CRIMINAL PROCEEDINGS OF DOCTORS PARTICIPATING IN INHUMANE EXPERIMENTS ON WW2 PRISONERS]
- 1946 — 1953 RADIOACTIVE CEREAL EXPERIMENTS AT FERNALD** [MENTALLY DISABLED CHILDREN FED RADIOACTIVE CEREAL]
- 1956 — 1972 WILLOWBROOK EXPERIMENT** [MENTALLY DISABLED CHILDREN DELIBERATELY INFECTED WITH HEPATITIS]
- 1956 — 1962 THALIDOMIDE EFFECTS** [MANUFACTURERS REQUIRED TO ESTABLISH DRUG'S EFFECTIVENESS PRIOR TO MARKETING]
- 1961 — 1962 MILGRAM STUDY** [SOCIAL SCIENCE STUDY TO UNDERSTAND ROLE OF OBEDIENCE TO AUTHORITY ]
- 1963 JEWISH CHRONIC DISEASE HOSPITAL** [INJECTION OF LIVE CANCER CELLS INTO INDIGENT, CHRONICALLY ILL ELDERLY PATIENTS]
- 1971 STANFORD PRISON EXPERIMENT** [PSYCHOLOGY OF IMPRISONMENT – MOCK PRISON WITH VOLUNTEER COLLEGE STUDENTS]
- 1995 US RADIATION EXPERIMENTS DISCLOSED** [RADIATION EXPERIMENTS ON THOUSAND'S OF US CITIZENS DURING WW2]
- 1998 JESSE GELSINGER** [18 YEAR OLD DIED FROM GENE TRANSER EXPERIMENT EVEN THOUGH DISEASE WAS NOT SEVERE]
- 2001 ELLEN ROCHE** [HEALTHY VOLUNTEER GIVEN DRUG TO INDUCE A MILD ASTHMA ATTACK]
- 2003 SUPPORT** [COMPARATIVE EFFECTIVENESS RESEARCH ON PREMATURE INFANTS - INAPPROPRIATE RANDOMIZATION?]
- 2005 — 2009 HAVASUPAI SETTLEMENT** [BLOOD COLLECTED IN 1990'S TO STUDY DIABETES WAS USED FOR UNRELATED STUDIES]
- 2010 GUATEMALA SYPHILIS STUDY EXPOSED** [IN 1940'S GUATEMALANS DELIBERATELY INFECTED WITH STD ORGANISMS]
- 2010 THE IMMORTAL LIFE OF HENRIETTA LACKS** [CANCER CELLS FROM HENRIETTA LACKS ORIGINATORS OF THE HELA CELL LINE]
- 2014 — 2016 EBOLA OUTBREAK** [RAPID APPROVAL OF CLINICAL TRIALS IN AFFECTED AREAS RESULTING IN UNPROVEN THERAPIES]
- 2014 FACEBOOK EMOTIONAL CONTAGION STUDY** [NEWS FEEDS OF OVER 600,000 FACEBOOK USERS MANIPULATED]
- 2018 CRISPR EXPERIMENT** [EMBRYONIC GENOME EDITING]
- 2019 SARS-COV-2 PANDEMIC** [EMERGENCY USE OF NEW DRUGS &THERAPIES]

PRIM&R Research Ethics Timeline

# Ethics in Research – Historical Perspective

**Tuskegee Study, 1932-1973**, PHS natural progression study of untreated syphilis in African American men. The men were not told of their diagnosis or possible treatments, spinal taps to assess for neurosyphilis were described as “special free treatment” and penicillin became the drug of choice for syphilis in 1947, but researchers did not offer treatment to the research subjects even though the study didn’t end until 1972.

**Stuttering Study, 1939**, This social science experiment set out to prove that stuttering is a learned behavior that can be induced through psychological pressure. This theory was tested on 22 children at Iowa’s Soldiers’ Orphans’ Home. The children were subjected to steady harassment and badgering in an attempt to get them to stutter.

**Willowbrook Hepatitis Study, 1950s**, Cognitively impaired children (5-10 yrs old) were intentionally given hepatitis in order to track the development of the viral infection. The study began in 1956 and lasted for 14 years.

(The results eventually contributed to the development of a successful vaccine.)

**These examples demonstrate inadequate or non-existent informed consent and unjust distribution of risk to vulnerable populations.**

# Ethics in Research – Historical Perspective

## **Jesse Gelsinger – 1999, Gene therapy**

Teenager died 4 days after receiving gene therapy. The researchers had earlier told the FDA they would tighten up the trial's eligibility criteria, but they never followed through. When two patients suffered serious side effects, the scientists did not put the study on hold as required. It turned out Jesse's pretrial test results showed he had poor liver function, indicating he shouldn't have received the gene injection.

- **Audit findings cited an inadequate informed-consent process. Researchers hadn't told Jesse about the earlier patients' side effects. Study investigator was accused of a conflict of interest: he had a stake in the company that owned the gene-transfer technology and stood to benefit if the trial succeeded.**
- **Gene therapy research in the U.S. was drastically affected and delayed by this one event**

# Ethics in Research – Historical Perspective

## CRISPR TECHNOLOGY - FIRST GENE-EDITED BABIES

2018

- Contrary to the scientist's claim, the aim of his experiments was not to treat any serious genetic disease. There was in fact no medical necessity of the experiment at the outset.
- Questions remain regarding the content of the informed consent process, whether there was institutional oversight, and the presence of political pressure on the scientist from the Chinese government to “be the first” to use this technology.
- Debate began related to the ethical dilemma of whether allowing parents to choose to genetically alter their future children can be ethical if they're not the one who is having their DNA changed.

**This scientist's actions led to a call for a moratorium on editing human germline cells to produce genetically modified babies.**

Why Human Germline Editing Might Never Be Legal in the U.S. By Jennifer M. Gumer, The Hastings Center Bioethics Forum, Published on August 9, 2019 .

# Ethics in Research – Recent Perspective

## SARS – COV-2 PANDEMIC

- Under tested or poorly studied treatments were publicized and politicized as proven and legitimate
- Unverified or impetuously authorized testing kits flooded the market
- EUA is not the same as FDA approved - messaging gets lost
- Retraction of several published articles due to questionable research practices
- Initial Astra-Zeneca vaccine efficacy data from the US is questioned by DSMB

### THE LANCET

Retraction – Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

This article was retracted because questions were raised related to the authenticity and reliability of the data and analyses. The company that performed the analysis refused to share the dataset and other documentation when requested by the journal. An independent and private peer review was not allowed to proceed, and the article was retracted.



# Ethics in Research – Historical Perspective

**Lack of Ethics in Research**



**Lack of Trust in Research**

Fortunately, ethical standards do not remain fixed; they transform in response to evolving situations, so we continue to revise measures to improve transparency and trust with the research participants. It is important to revisit the beginning of the modern story of human subjects protection starting with the Nuremberg code of 1947.

# Ethics in Research – Historical Perspective

The *Nuremberg Code* (of 1947), was developed for the Nuremberg Military Tribunal as the standard by which to judge the human experimentation conducted by the Germans. The code includes 10 provisions.

The Code provides details implied by such a requirement:

- capacity to consent;
- freedom from coercion;
- and comprehension of the risks and benefits involved.

Other provisions require:

- the minimization of risk and harm;
- a favorable risk / benefit ratio;
- qualified investigators using appropriate research designs;
- and freedom for the subject to withdraw at any time.



[Hermann Göring](#)  
under cross-examination

# Ethics in Research – Historical Perspective

Similar recommendations were made by the World Medical Association in its Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects – first adopted in 1964.

1964

1974

In the U.S., regulations protecting human subjects first became effective in 1974. The regulations established the IRB as one mechanism through which human subjects would be protected.

# Ethics in Research – Historical Perspective

The **National Research Act**, passed in 1974, led to the issuance of **The Belmont Report** which set forth the basic ethical principles of respect for persons, beneficence, and justice.

**Respect for persons** involves a recognition of the personal dignity and autonomy of individuals, and special protection of those persons with diminished autonomy. This principle underlies the need to obtain informed consent.

**Beneficence** entails an obligation to protect persons from harm by maximizing anticipated benefits and minimizing possible risks of harm. This principle underlies the need to engage in a risk / benefit analysis and to minimize risks.

**Justice** requires that the benefits and burdens of research be distributed fairly. This principle requires that subjects be fairly selected.

# Ethics in Research – Key Element - IRB

An Institutional Review Board is a federally mandated committee that oversees research at an institution. The role of the IRB is to protect the rights and welfare of human research subjects involved in research activities

- UTGSM IRB includes 28 members: Physicians, nurses, pharmacists, scientists, non-scientists and community members.
- Office for Human Research Protections (OHRP) and the FDA oversee IRB functions at academic institutions with federal funding and will perform periodic audits. The OHRP and FDA may halt or suspend research not in compliance. Investigators and institution can be sanctioned and reputation damaged.
- Local audits performed by IRB staff – (not for-cause audits and for-cause audits) may result in recommendations for the investigator or possible suspension of research until issues are resolved.

**The IRB is only one part of the research enterprise designated to protect human research subjects.**

# Ethics in Research – Key Element - Faculty

**Faculty members who supervise student research also have an obligation to consider carefully whether their students or residents are adequately qualified to safeguard the rights and welfare of research participants.**

**Faculty should provide instruction and guidance which includes:**

- **Ensuring the identified subject population is the appropriate source of data to answer the research question.**
- **Checking the planned method for data collection is valid and will yield data that answers the study question**
- **Verifying that the planned analysis of the data is appropriate and will answer the study question**
- **Monitoring the progress of the study and providing oversight in the conduct of the research**
- **Having current CITI training**

# Ethics in Research – Key Element - PI

In submitting a new study/project application or revision for review and approval by the UTGSM IRB, as principal investigator you agree to assume the following responsibilities and to faithfully execute them in accord with applicable federal regulations for the protection of human subjects and UTGSM IRB policies and procedures:

1. To conduct the research according to the IRB-approved protocol;
2. To obtain and document the informed consent and/or assent of subjects or subjects' legally authorized representatives, using the UTGSM IRB-approved informed consent process and documents, prior to the subjects' participation in any research procedures, unless these requirements have been altered or waived by the IRB;
3. To obtain prior approval from the IRB for any modifications of previously approved research, including modifications to the informed consent process and documents.
4. To ensure that progress reports and requests for continuing review and approval are submitted in the time frame and the manner prescribed by the IRB, but no less than once per year;
5. To provide the IRB with prompt reports of any unanticipated problems involving risks to subjects or others, including adverse events and protocol deviations;
6. To provide the IRB with prompt reports of serious or continuing noncompliance with the federal regulations for the protection of human subjects or the requirements or determinations of the IRB;
7. To notify the IRB regarding the completion of the study/project;
8. To maintain study/project records for the specific lengths of time denoted in the IRB's "Responsibilities of Investigators" policy regarding all records, consent forms, drug study records, and device study records;
9. To assure that all collaborating investigators and other key research personnel involved in the research study/project are fully informed regarding: (a) the study/project procedures; (b) informed consent requirements; (c) the potential adverse events associated with study/project participation and the steps necessary to minimize potential risks; (d) reporting requirements for unanticipated problems; and (e) data collection and record-keeping requirements;
10. To assure that all key research personnel personally complete required training regarding the protection of human subjects prior to their initiation of study/project activities;
11. To disclose to the IRB all conflicts of interest as defined in institutional policy that may relate to the conduct of the research; and
12. To permit inspection and audit of all records related to the conduct of the study/project by authorized representatives of the IRB and departments or agencies supporting or conducting the research.

# Ethics in Research – Key Element - PI

- To conduct the research according to the IRB-approved protocol – this serves as a roadmap
- To maintain study records (including data collection, sharing & storage)
- To assure all key study personnel are fully informed of procedures

In submitting a new study/project application or revision for review and approval by the UTGSM IRB, as principal investigator you agree to assume the following responsibilities and to faithfully execute them in accord with applicable federal regulations for the protection of human subjects and UTGSM IRB policies and procedures:

1. To conduct the research according to the IRB-approved protocol;
2. To obtain and document the informed consent and/or assent of subjects or subjects' legally authorized representatives, using the UTGSM IRB-approved informed consent process and documents, prior to the subjects' participation in any research procedures, unless these requirements have been altered or waived by the IRB;
3. To obtain prior approval from the IRB for any modifications of previously approved research, including modifications to the informed consent process and documents.
4. To ensure that progress reports and requests for continuing review and approval are submitted in the time frame and the manner prescribed by the IRB, but no less than once per year;
5. To provide the IRB with prompt reports of any unanticipated problems involving risks to subjects or others, including adverse events and protocol deviations;
6. To provide the IRB with prompt reports of serious or continuing noncompliance with the federal regulations for the protection of human subjects or the requirements or determinations of the IRB;
7. To notify the IRB regarding the completion of the study/project;
8. To maintain study/project records for the specific lengths of time denoted in the IRB's "Responsibilities of Investigators" policy regarding all records, consent forms, drug study records, and device study records;
9. To assure that all collaborating investigators and other key research personnel involved in the research study/project are fully informed regarding: (a) the study/project procedures; (b) informed consent requirements; (c) the potential adverse events associated with study/project participation and the steps necessary to minimize potential risks; (d) reporting requirements for unanticipated problems; and (e) data collection and record-keeping requirements;
10. To assure that all key research personnel personally complete required training regarding the protection of human subjects prior to their initiation of study/project activities;
11. To disclose to the IRB all conflicts of interest as defined in institutional policy that may relate to the conduct of the research; and
12. To permit inspection and audit of all records related to the conduct of the study/project by authorized representatives of the IRB and departments or agencies supporting or conducting the research.



# Ethics in Research – Key Element - PI

Similar to Faculty responsibilities, an investigator should consider several pieces of their project that could impact the research participants.

- Co-Investigator/study personnel selection - research experience, subject specific knowledge, attention to detail, availability to dedicate time to research
- Study Design – what is appropriate? secondary or primary research, observational, experimental?
- Study Population - carefully consider inclusion/exclusion criteria, vulnerable populations, diversity – extra care & extra time involved
- Data Collection – how will you securely access, collect, share and analyze data? Excel, REDCap, UHS OneDrive, Encryption, Passwords
- Data Analysis - garbage in = garbage out. Appropriate use of statistics is a must, consider a biostatistician from the start

All of these should be carefully considered prior to IRB submission

# Navigating the IRB Process – Common Delays

- Study team members do not have **current** CITI training  
<https://www.citiprogram.org>
  - Group 3: Investigators and key Study Personnel
  - Group 4: Fellows, Residents and Students
  - GCP: Federally funded/Clinical Trials
- Selecting the wrong IRB
  - Select UT GSM/UTMC Knoxville **or else we won't get it!**
- Email address not associated with you
  - Go to profile and check email address \*\*\*\*@utmck.edu
- Selecting a review type that is not applicable – these are generally based on risk level – call if unsure
  - Exempt → Expedited → Full Board

# Navigating the IRB Process – Common Delays

- Failing to adequately explain what you intend to do  
→ read iMedRIS questions and instructions carefully
- Forgetting to attach supporting documents  
→ surveys, consents, protocols, data collection sheets
- Forgetting to route for signatures  
→ \*\* (Residents: PI, Faculty Advisor & Department Chair must sign-off)\*\*  
New in 2020 – not all study personnel are required to sign-off
- Study team does not sign-off in a timely manner  
→ (the IRB office does not receive your application until all sign-offs are completed so we probably won't know the existence of your project!)
- Not checking the status of your project  
→ contact the IRB office to verify IRB receipt if more than a week goes by

# Navigating the IRB Process - iMedRIS

1

- To get started, click on the iMedRIS link:  
<https://imedris.uthsc.edu>
- iMedRIS can also be accessed from the IRB Website

2

- Helpful hints:
- Chrome is the browser of choice
- Turn popup blockers off

3

- iMedRIS uses 2-factor authentication so you must have your UT NetID and Password. If your password is not current, it must be reset
- You will either receive a DUO push or passcode

# Navigating the IRB Process - iMedRIS

### Central Authentication Service

NetID:

Password:

**LOGIN**


By logging in to this site, you agree to the terms of the UT Acceptable Use Policy.

### imedris-production

iMedRIS Production

[Forget your password?](#)

[Need help signing in?](#)



### Choose an authentication method

Duo Push ✓ Used automatically

Passcode

Remember me for 7 days

[What is this?](#) [Add a new device](#) [My Settings & Devices](#) [Need help?](#)

Pushed a login request to your device...

# Navigating the IRB Process - iMedRIS

To get started, once in iMedRIS, click on the create a new project tab – (you may want to check profile to see if your information is correct)

The screenshot displays the iMedRIS application interface. At the top, the browser address bar shows the URL `imedris-training.uthsc.edu/Application_Main.jsp?s=1604670289341`. The user is logged in as "Hello Jacqueline Marie Van Aud..." with a last login time of "10-29-2020 09:29". The navigation menu includes "My Workspaces", "Project Assistant", "Help", "Tutorial", "My Profile" (circled in orange), and "Log out".

The main content area is divided into two sections:

- Featured Project Operations:** A list of actions including "Create a New Project", "Start a Project Submission Form", "View My Projects", "View My Projects Submissions", "Track Approvals", and "Forms Pending Submission" (with a red badge showing the number 9).
- Tasks:** A list of tasks including "View All Tasks" (with a red badge showing 15) and "View Project Tasks" (with a red badge showing 15).

At the bottom, there is a "Project Assistant" header with a settings gear icon. The Windows taskbar at the very bottom shows the time as 8:46 AM on 11/6/2020.

# Navigating the IRB Process - iMedRIS

Select UT GSM/UTMCK study application for human research conducted at UT Medical Center Knoxville or UT Graduate School of Medicine

**\*\*IF YOU MAKE THE WRONG CHOICE, WE WILL NOT RECEIVE YOUR APPLICATION\*\***

Account: Jacqueline Marie Van Audenhove, MS  
Department: UT GSM - GSMK - Clinical Ethics  
Path: Home

Help My Profile Log out

My Workspaces Project Assistant **Select New Project Application Form** Back

Cancel and Return Start selected Application

**Please select a New Project Application from the list below:**

Form Name	Form Description
<input type="radio"/> UTHSC IRB Memphis Form 1: Study/Project Application	UTHSC, LeBonheur Children's Hospital, Methodist Healthcare - Memphis Hospitals, or Regional One Health - Health Science Center Institutional Review Board (IRB)
<input type="radio"/> UTK Knoxville Main Campus IRB Application	Knoxville Institutional Review Board (IRB)
<input checked="" type="radio"/> UT GSM/UTMC Knoxville: IRB Study Application	Submission form for human research conducted at UT Medical Center Knoxville or UT Graduate School of Medicine
<input type="radio"/> UTHSC IBC PROTOCOL APPLICATION	Health Science Center - Memphis Institutional Biosafety Committee (IBC)
<input type="radio"/> UTK - Institutional Biosafety Committee Registration	Knoxville Institutional Biosafety Committee (IBC)
<input type="radio"/> UTHSC IACUC Protocol	Health Science Center (Memphis) Institutional Animal Care and Use Committee (IACUC)
<input type="radio"/> UTHSC Radiation Safety	UTHSC (Memphis) Application for the Use of Radioactive Materials

# Navigating the IRB Process - iMedRIS

At section 1.0, enter full project title. Underneath, enter a short working title you may want to use with study team.

The screenshot shows a web browser window with the URL [https://imedris-training.uthsc.edu/Study\\_App.jsp?FORM\\_MODE=EDIT&tab=section&ss=1565031591742](https://imedris-training.uthsc.edu/Study_App.jsp?FORM_MODE=EDIT&tab=section&ss=1565031591742). The user is logged in as Jacqueline M Van Audenhove, Department: UT GSM - GSMK - Research Center. The page title is "UT GSM / UHS Knoxville: IRB Study Application (Version 1.0)".

The "1.0 General Information" section contains the following instructions and input fields:

- Instruction:** \* Please enter the full title of your study. For UT GSM (Knoxville) projects, include the generic/trade name of the HUD; the name of the device/drug for Treatment Use; the name of the device for Compassionate Use; or the name of the device/drug for Emergency Use.
- Input Field 1:** Training Session Application Form 1
- Instruction:** \* Please enter a working title up to 15 characters.
- Input Field 2:** TSA Form 1

Two orange arrows point to the input fields from the left side of the screen.



# Navigating the IRB Process - iMedRIS

At section 2.0, the department will default to your department. You can also add other departments as applicable to your project

The screenshot displays the iMedRIS web application interface. The browser address bar shows the URL: [https://imedris-training.uthsc.edu/Study\\_App.jsp?FORM\\_MODE=EDIT&tab=sections&=1565031591742](https://imedris-training.uthsc.edu/Study_App.jsp?FORM_MODE=EDIT&tab=sections&=1565031591742). The user is logged in as Jacqueline M Van Audenhove, Department: UT GSM - GSMK - Research Center, Path: Home. The page title is "UT GSM / UHS Knoxville: IRB Study Application (Version 1.0)".

The main content area is titled "2.0 Add Department(s)". It includes instructions: "2.1 List all departments and affiliate institutions associated with this study/project. Mark the Principal Investigator's UTHSC department as the primary department. If any of your study/project activities are being conducted at the following sites, list these organizations as well: Methodist and/or Le Bonheur, Regional One Health, Clinical Research Center (CRC), Office of Clinical Research, UTMG, Graduate School of Medicine, University Health System, University of Tennessee, Knoxville, Oak Ridge National Laboratories, University Family Physicians, UT Genetics Center, et al."

Below the instructions is a table with the following structure:

Is Primary?	Department Name	
<input type="checkbox"/>	<input checked="" type="radio"/> UT GSM - GSMK - Research Center	<span>+ Add</span> <span>- Remove</span>

The "Add" and "Remove" buttons in the table are circled in orange. An orange arrow points from the top left towards the "Add" button.

# Navigating the IRB Process - iMedRIS

At section 3.0, add your project team by clicking on Setup Project Personnel

The screenshot displays the iMedRIS interface for a user named Jacqueline Marie Van Audenhove. The top navigation bar includes the University of Tennessee logo, account information, and utility links like Help, My Profile, and Log out. Below this, a breadcrumb trail shows 'My Workspaces' > 'Working Title: FBT4C Fall2020' > 'Project Assistant' > 'UT GSM/UTMC Knoxville: IRB Study Application (Version 1.0)'. A 'Back' button is visible in the top right of the breadcrumb area.

The main content area is divided into two tabs: 'Section view of Application' (selected) and 'Entire view of the Application'. The left sidebar lists sections 1.0 (General Information), 2.0 (Setup Department(s) Access), and 3.0 (Grant Key Personnel access to the study), with 3.0 highlighted.

Section 3.0 is titled '3.0 Assign key study personnel(KSP) access to the study'. A button labeled 'Setup Project Personnel' is circled in orange and pointed to by a callout box containing the text 'Easily overlooked'. Below this, section 3.1 is titled '3.1 \* Please add a Principal Investigator for the study:'. The form shows the name 'Jacqueline Marie Van Audenhove' and a list of roles: Student, Resident, Department Chair, and Fellow. The 'Fellow' role is selected with a checked checkbox. A note states: 'If the Principal Investigator is a Student, Resident, or Fellow, the name of the Faculty Advisor must be supplied below.' Section 3.2 is titled '3.2 If applicable, please select the Research Staff personnel:' and includes sub-sections A) Additional Investigators and B) Research Support Staff.

# Navigating the IRB Process - iMedRIS

To add personnel, you must search in the iMedRIS or LDAP directory. After identifying who you want to add, click on the yellow folder. Repeat this for each additional person involved in the study.

The screenshot displays the 'Setup Project Personnel' interface in a web browser. The browser address bar shows the URL: `imedris-training.uthsc.edu/Study_App.jsp?FORM_MODE=EDIT&tab=section&cs=1604671153127`. The interface includes a search form with the following fields:

- Last Name: Van
- First Name: Jacque
- Department: All Departments
- Search From:  iMedRIS Database  LDAP Directory

A button labeled 'Find User/Search Directory' is circled in orange. Below the search form, a list of search results is displayed, with a yellow folder icon circled in orange. The search results include the following information:

Name	Role
Van Audenhove, Jacqueline Marie	Medical Library, Medicine, Medicine - Genetics, Medicine - Pulmonary, Mother-Baby (3 East), Neonatal Intensive Care Unit (NICU), Neonatology, Nephrology, Neurology, Neuroscience, Nuclear Medicine, Nursing, Nursing, Nursing, Office of Clinical Trials, Oral & Maxillofacial Surgery, Pediatrics, Pharmacy, Pharmacy, Physical Medicine, Psychiatry, Radiology, Radiosurgery, Regional Perinatal Program, Rehabilitation

The 'Selected Project Personnel' section is empty, showing 'No Personnel has been selected for this group.' for both Principal and Additional Investigators. The interface also includes a 'My Profile' dropdown, a 'Log out' button, and a 'Back' button. The bottom of the screen shows the Windows taskbar with the search bar and various application icons.

# Navigating the IRB Process - iMedRIS

Jacque has been added as PI. Continue to add all study personnel and assign roles for each.

**Setup Project Personnel**

User Search  
Create My Personnel Pool

Last Name: Van First Name: Jacque  
Department: All Departments  
Search From:  iMedRIS Database  LDAP Directory

Find User/Search Directory

Selected Project Personnel:

Name	Role
Van Audenhove, Jacqueline Marie	Principal Investigator

Additional Investigators

Name	Role
No Personnel has been selected for this group.	

Clear Key Project Personnel Close Setup of Project Personnel

# Navigating the IRB Process - iMedRIS

At section 4.1, note who will be obtaining consent and who will have access to research records. Anyone obtaining consent or viewing PHI must be included on your study application and approved by the IRB.

Print Friendly   Save Section   Save and Continue to Next Section

Entire view of the Application

### 4.0 (400) UTGSM Key Study Personnel Contact Information

revised: 11/19/2020

4.1 \* For the Principal Investigator, the Project Contacts, and all Key Study Personnel, provide the following information: Note: All iMedRIS correspondence will be sent automatically to your UT email account. You may contact the HELP Desk at 1-800-413-7830 to have your UT email forwarded to another account at UHS, yahoo, gmail, etc.

Add a new row   Copy existing row(s)   Delete selected row(s)

	Name	Will obtain informed consent	Access to research records
<input type="checkbox"/>	Van Audenhove, Jacqueline Marie	N/A	Yes
<input type="checkbox"/>	Langley, Cynthia L, RN, CIP	N/A	Yes

# Navigating the IRB Process - iMedRIS

At section 5.2, indicate if you will be getting a collaboration form or department letter of support/approval. This applies when you need departmental assistance beyond standard of care.

## 5.0 (403) Additional UTGSM / UHS Committee or Department Approvals

5.1 GSM Requires completed, signed Collaboration forms or letters of support as indicated below. These are due at the time of IRB submission and should be attached to the Submission Routing Form at the end of the application.

Collaboration forms are available on the IRB Website at <http://gsm.utmck.edu/irb/forms>.  
Letters of support may be letters or emails saved as a PDF.

- Infection Prevention/Control: **Letter of Support**, contact Mark Rasnake, MD at 305-7655 or [mrasnake@utmck.edu](mailto:mrasnake@utmck.edu) with questions regarding support from Infection Prevention.
- Nursing (supporting other departments): **Collaboration Form**, if you need support/assistance AND Leslie McKeon, PhD, RN, submit a collaboration form signed by the Nurse Manager for the area where you need assistance AND Leslie McKeon, PhD, RN.
- Nursing (Research by Nurses): **Approval Letter** Present your project to the Nursing Research Council (NRC) before submitting your IRB application and attach a copy of the NRC approval letter with your application. Contact Leslie McKeon at [LMcKeon@utmck.edu](mailto:LMcKeon@utmck.edu) for questions regarding the review by the Nursing Research Council.
- Pathology: **Collaboration Form**, contact Dr. Amila Orucevic at 305-9080 or [AOrucevic@utmck.edu](mailto:AOrucevic@utmck.edu) with questions regarding the Pathology Collaboration form.
- Pharmacy: **Collaboration Form**, contact Dr. Barbera Faircloth at 305-8380 or [BFairclo@utmck.edu](mailto:BFairclo@utmck.edu) with questions regarding the Pharmacy Collaboration form.
- Radiology: **Collaboration Form**, contact Dustin Osborne, PhD at 305-8264 or [DOsborne@utmck.edu](mailto:DOsborne@utmck.edu) with questions regarding the Radiation Collaboration form and review by the Radiology Research Committee.
- Radiation Safety: **Approval Letter**, contact Stephen Handley at 305-9664 or [SHandley@utmck.edu](mailto:SHandley@utmck.edu) with questions regarding review by Radiation Safety.
- Simulation Center: **Collaboration Form**, contact Melinda Klar at 305-4626 or at [MKlar@utmck.edu](mailto:MKlar@utmck.edu) with questions regarding the SIM Center form.

## 5.2 Collaboration forms and/or approval letters (check all that apply).

- NA
- Pharmacy Review (Collaboration form)
- Pathology (Collaboration form)
- Radiology Department (Collaboration form)
- Radiation Safety Review (Approval letter)
- O.R. Committee (Device Trials) (Approval letter)
- Infection Control Committee (Approval letter)
- Nursing (Collaboration form)
- Nursing Research Council (UHS Nursing only) (Approval form)
- Advanced Medical Simulation Center

# Navigating the IRB Process - iMedRIS

**At section 5.3, indicate participating Centers of Excellence as it applies to your research project.**

**5.3 \* Please select any participating Centers of Excellence below.**

- NA
- Brain and Spine
- Cancer
- Emergency and Trauma
- HLIV
- Orthopedic
- Women and Infants

# Navigating the IRB Process - iMedRIS

At section 6.1, indicate why you are filling out the application. For initial submissions, you select the first option. At section 6.2, indicate if you will be using data from another study to include in this study. If yes, explain how the previous data is related to the new data to be collected.

## 6.0 (418) UTGSM IRB Submission

6.1 \* Please indicate the correct status of this submission: **Note: If you are submitting a Form 2 for revision, DO NOT change your answer in this section.**

- I am requesting initial approval for research.
- I am registering a research study that will be ceded to another IRB through a Reliance Agreement
- I am requesting initial approval for the use of a Humanitarian Use Device (HUD).
- I am notifying the IRB regarding the emergency use of an investigational device.
- I am notifying the IRB regarding the emergency use of an investigational drug, or biologic.
- I am requesting approval for compassionate use of an unapproved medical device.
- I am requesting approval for the treatment use of an unapproved medical device.
- I am requesting approval for the treatment use of an unapproved drug or biologic.
- I am registering the use of an anonymized human cell line purchased or acquired from commercial vendors, IRB approved repositories or government tissue banks.

6.2 Is this proposal associated with any other IRB-approved studies?

- Yes
- No



# Navigating the IRB Process - iMedRIS

At section 7.0, indicate the level of review (Exempt, Expedited, or Full Board) and type of study. If you aren't sure, call the IRB office. Most chart review studies are Exempt. At section 8.0, indicate if there is a funding source. This includes a source providing drugs or a device.

7.0 (419) Level of IRB Review	
7.1 * Are you requesting Full Board, Expedited or Exempt review by the IRB?	
<input checked="" type="radio"/> Exempt <input type="radio"/> Expedited (Minimal Risk to Subjects) <input type="radio"/> Full Board (Greater than Minimal Risk to Subjects)	
7.2 * Please indicate the type of study:	
<input checked="" type="radio"/> No drug/biologic or device is being administered and evaluated as part of study procedures. <input type="radio"/> A device is being administered and evaluated as part of the study procedures. <input type="radio"/> A drug/biologic is being administered and evaluated as part of the study procedures. <input type="radio"/> A drug/biologic AND a device is being administered and evaluated as part of the study procedures.	

8.0 (460) Funding Source	
8.1 Is there a funding source associated with the study? This includes a source that will provide study drug/biologic/device at no cost.	
<input type="radio"/> Yes <input checked="" type="radio"/> No	

# Navigating the IRB Process – Review Levels

## Exempt - Less than minimal risk to subjects

- 8 Categories – **Category 4 most often used (secondary use of data)** – may choose more than one category. Category 1: [Educational Settings - FERPA], **Category 2: [Surveys]** Category 3: [Benign Behavioral Interventions]
- Waiver of HIPAA authorization might apply (chart review studies)
- No Continuing Review but given a 3 year expiration date at that time closed or renewed
- **IRB deadlines do not apply (study does not go to convened IRB meeting)**

## Expedited - Minimal risk to subjects

- 7 Categories – may choose more than one – minimally invasive (e.g. blood draw)
- Waiver/Alteration (verbal) of Consent & Waiver/Alteration of HIPAA Authorization may apply
- No requirement for Continuing Review every year unless specified in outcome letter
- **IRB deadlines do not apply (study does not go to convened IRB meeting)**

## Full Board - Greater than minimal risk to subjects – drug / device trials

- Continuing Review every year
- **IRB deadlines do apply – will be reviewed at a convened IRB meeting**

# Navigating the IRB Process - iMedRIS

At section 9.0, describe purpose & rationale, study population, method of recruitment, research design & procedures, and outcome measures.

The screenshot displays the iMedRIS web application interface. At the top, the University of Tennessee logo is on the left, and user information (Account: Jacqueline M Van Audenhove, Department: UT GSM - GSMK - Research Center) and navigation links (Help, My Profile, Log out) are on the right. Below this is a teal header bar with 'My Workspaces', 'Working Titles: TSA Form 1', 'PE: Van Audenhove, Jacqueline M', 'Project Assistant', and the current application title 'UT GSM / UHS Knoxville: IRB Study Application (Version 1.0)'. A 'Back' button is also present. Below the header, there are buttons for 'Print Friendly', 'Save Section', and 'Save and Continue to Next Section'. The main content area is divided into two tabs: 'Section view of Application' and 'Entire view of the Application'. The left sidebar shows a list of sections from 1.0 to 9.0, with 9.0 'Request for Exemption' selected. The main content area shows the details for section 9.0, including a note about medical records, a purpose of study (Training - faculty), a description of the subject population (Chart Review, expected number ~200), methods of recruitment (Chart review, no recruitment), research design/procedures (After IRB approval, data will be stored on a password-protected spreadsheet/RedCap on OneDrive), and outcome measures (Outcome measures per biostatistician on project).

Account: Jacqueline M Van Audenhove  
Department: UT GSM - GSMK - Research Center  
Path: Home > project mgmt.

Help My Profile Log out

My Workspaces Working Titles: TSA Form 1 PE: Van Audenhove, Jacqueline M Project Assistant UT GSM / UHS Knoxville: IRB Study Application (Version 1.0) Back

Print Friendly Save Section Save and Continue to Next Section

Section view of Application Entire view of the Application

1.0 General Information  
2.0 Setup Department(s) Access  
3.0 Grant Key Personnel access to the study  
4.0 (400) UTGSM Key Study Personnel Contact Information r ...  
5.0 (403) Additional UTGSM / UHS Committee or Department Approva ...  
6.0 (418) UTGSM IRB Submission  
7.0 (419) Level of IRB Review  
8.0 (460) Funding Source  
9.0 (610) Request for Exemption

9.0 (610) Request for Exemption

9.1 Note: Medical records cannot be accessed until the IRB has approved this request.

9.2 \* Purpose of Study and Rationale  
Training - faculty

9.3 \* Description of Subject Population If chart review only, list beginning and ending dates of review. If open-ended prospective collection, until how many records have been reviewed?  
Chart Review. Expected number ~200. All patients with ICD10 code XX.X from January 2018-January 2020

9.4 Methods of Recruitment (if applicable)  
Chart review. No recruitment.

9.5 \* Research Design / Procedures  
After IRB approval I will review applicable records and collect data that will be stored on a password protected spreadsheet/RedCap on OneDrive on an encrypted hospital computer.

9.6 \* Outcome Measures - State what statistical method will be used to analyze the data. Contact Eric Heidel, PhD for statistical consultation at rheidel@utmck.edu or 865-305-3474.  
Outcome measures per biostatistician on project.

# Navigating the IRB Process - iMedRIS

At section 10.0, if you chose an Exempt level of review, you must select the appropriate category. Most chart review studies are Category 4 (select section 10.5). If viewing medical records, you will need to select sub-category (iii).

## 10.0 (615) Exempt Category

10.1 \* Check the appropriate Exempt Category:

10.5 Category 4) Secondary research for which consent is not required: Secondary research uses of identifiable private information or identifiable biospecimens, if at least one of the following criteria is met:

- (i) The identifiable private information or identifiable biospecimens are publicly available;
- (ii) Information, which may include information about biospecimens, is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator does not contact the subjects, and the investigator will not re-identify the subjects (No identifiers or Medical Records will not be used.);
- (iii) The research involves only information collection and analysis involving the investigator's use of identifiable health information when that use is regulated under HIPAA for the purposes of "health care operations" or "research" as defined or for "public health activities and purposes" as described (Medical Records will be reviewed), or:
- (iv) The research is conducted by, or on behalf of, a Federal department or agency using government-generated or government-collected information obtained for nonresearch activities.

# Navigating the IRB Process - iMedRIS

**At this point, you will be prompted to select either:  
A HIPAA Authorization will be obtained from subjects or  
A Request for Waiver of Authorization is requested.  
If selecting a Waiver of Authorization, the criteria for this  
waiver must be satisfied for the IRB to approve a waiver.**

Yes

Clear

Choose at least one:

i

ii

iii

iv

Select one:

A HIPAA Authorization will be obtained from subjects

A Request for Waiver of Authorization is requested

# Navigating the IRB Process - iMedRIS

The following three criteria must be satisfied for an IRB to approve a waiver of authorization under the Privacy Rule:

- The use or disclosure of protected health information involves no more than a minimal risk to the privacy of individuals, based on, at least, the presence of the following elements:
  - ✓ an adequate plan to protect the identifiers from improper use and disclosure;
  - ✓ an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention is otherwise required by law; and
  - ✓ adequate written assurances that the protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted by this subpart;
- The research could not practicably be conducted without the waiver or alteration; and
- The research could not practicably be conducted without access to and use of the protected health information.

# Navigating the IRB Process - iMedRIS

At section 11.0 & 12.0, if a HIPAA waiver is requested, you will be asked to describe the justification for the waiver

## 11.0 (3466) HIPAA Waiver or Alteration

11.1 \* Briefly describe the plan to protect the Protected Health Information (PHI) identifiers.

PHI will be stored on a password protected excel spreadsheet on an encrypted hospital computer with access only to key study personnel noted on this application.

11.2 \* Briefly describe the plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research. If there is a justification for retaining the identifiers or such retention is otherwise required by law, this should be explained.

Identifiers will be destroyed at the earliest opportunity once the investigators no longer need to use it. The remaining data will be kept per regulatory and institutional policy.

11.3 \* Will the Personal Health Information (PHI) be reused or disclosed to any other person or entity?

Yes  No

11.4 \* Is it true that the Personal Health Information (PHI) will not be reused or disclosed to any other person or entity EXCEPT as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of the PHI is approved by the IRB?

- True. PHI will not be reused or disclosed unless as excepted above.  
 Not true. PHI may be reused or disclosed as noted below.

11.5 \* Briefly explain why you must have access to the PHI in order to complete your research.

This is a chart review that requires access to pertinent PHI in order to conduct the research.

## 12.0 (3467) HIPAA Alteration Practicality

12.1 \* Briefly explain why the research activity could not practicably be conducted without alteration of the authorization requirement.

There isn't a feasible way to contact all potential subjects (some have died, left town, contact information not current) and sufficient personnel is not available to contact all subjects. Not including all subjects may skew data.

# Navigating the IRB Process - iMedRIS

At section 13.1, you can leave the text box blank and select save and continue to attach documents and route for signatures.

## 13.0 (10000) Save and Attach Documents

13.1 The following text box is provided in the event you need specific items listed on the approval form such as, Protocol with version and/or date, Informed Consent, version and/or date, Investigator Drug Brochure, Advertisements, etc.

**ALMOST DONE! USUALLY LEAVE  
THIS BLANK**

13.2 After clicking the "Save and Continue" button, you will advance to the routing form in order to attach any supporting documents (such as consent forms) and to send the submission to the necessary personnel for their signatures. CLICK on "Save and continue..."



# Navigating the IRB Process - iMedRIS

Your application form is complete and attached to a routing form automatically. At section 2.0, you can attach study documents like consents, surveys, protocols, data collection form.

**1.0 Routing Form**  
(100) Application

1.2 Please contact GSM IRB - (865) 305-9781 or (865) 305-6892 for assistance.

1.7 \* Please attach the study/project application form.

Unattach	Revise/ Attach	Edit/ View	Title
			UT GSM/UTMC Knoxville: IRB Study Application (Version 1.0)

**2.0 (1520) Study Documents**

2.1 Please attach any additional study documents.  
(protocol, investigator drug brochure, advertising, recruitment materials, tests, surveys, interview or focus group scripts, or observation instruments, etc.)

Document	Version	Title	Category	Expiration Date	Document Outcome	Checked Out	View Document
No Document(s) have been attached to this form.							

# Navigating the IRB Process

## HOW TO DE-IDENTIFY PHI?

Health information by itself **without the 18 identifiers** is not considered to be PHI. For example, a dataset of vital signs by themselves do not constitute protected health information. However, **if the vital signs dataset includes medical record numbers, then the entire dataset must be protected since it contains an identifier.**

### SAFE HARBOR – THE REMOVAL OF SPECIFIC IDENTIFIERS

The HIPAA compliant way to de-identify protected health information is to remove specific identifiers from the data set.

The identifiable data that must be removed are:


- Names
- Geographic subdivisions smaller than a state
- All elements of dates (except year)** related to an individual (including admission and discharge dates, birthdate, date of death, all ages over 89 years old, and elements of dates (including year) that are indicative of age)
- Telephone, cellphone, and fax numbers
- Email addresses
- IP addresses
- Social Security numbers
- Medical record numbers**
- Health plan beneficiary numbers
- Device identifiers and serial numbers
- Certificate/license numbers
- Account numbers including FINs**
- Vehicle identifiers and serial numbers including license plates
- Website URLs
- Full face photos and comparable images
- Biometric identifiers (including finger and voice prints)
- Any unique identifying numbers, characteristics or codes

In the case of zip codes, covered entities are permitted to use the first three digits provided the geographic unit formed by combining those first three digits contains more than 20,000 individuals.

# Navigating the IRB Process - iMedRIS

If you are finished, select “signoff and submit.” You will then select “YES” to route for additional signoff.

**Form has been Completed!**  
Instruction of Form has Been Completed Screen



Exit Form  
Signoff and Submit

Setup for Submission Routing and Signoff

Does this submission require additional routing for approval?

YES - Click YES to select additional personnel for routing.

NO - Click NO to bypass selecting additional personnel for routing.

Save Selection and Continue the Signoff Process



# Navigating the IRB Process - iMedRIS

Principal Investigator, Faculty Advisor and Department Chair must sign-off on all resident, fellow or student initial applications. If you listed them on the project application, their name should show up on this screen or you can add them.

### Setup for Submission Routing and Signoff

**i** This screen enables the collection of Key Personnel and Additional Personnel for Review and Signoff. The Check box "Checked" indicates the person is included in the signoff process. The Check box "Unchecked" indicates the person is not included in the signoff process. The Add Additional Personnel button is used to search from the user database and add them to the routing list. The order of the Additional Personnel is to create a review order for the assigned personnel. If personnel have 1 - 27 sequential.

**Select the Key Personnel for Submission Routing and Signoff:**

Include in signoff	Approved	Name	Role
<input checked="" type="checkbox"/>		 Jacqueline Marie Van Audenhove, MS	Principal Investigator
<input type="checkbox"/>		 Cynthia L Langley, RN, CIP	Co-Investigator

**Select Additional Personnel for Submission Routing and Signoff:** Add Additional Personnel to the Routing List

Include in signoff	Order	Approved	Name	Role
No additional personnel have been added to the signoff routing list.				

Cancel - Finalize later Save - Signoff Routing List


# Navigating the IRB Process - iMedRIS

This is your last chance to review signoff list. If you are ready to route for signatures, select yes and click on the save-start signoff routing tab.

**Setup for Submission Routing and Signoff** X

**i** This screen is for reviewing the signoff routing list. You must answer "Yes" or "No" to the finalization of the Personnel. Once the "Yes" selection is made the button "Save - Start Signoff Routing" becomes enabled to be clicked. Clicking the "Save - Start Signoff Routing" will start the routing list and then the submission board review(s). Clicking the "Go back to Make Changes" will place you back to editing the routing list. Clicking the "Cancel - Finalize later" will close this window. The submission process is incomplete.

**Finalize List of Personnel for Submission Routing and Signoff:**

Order	Approved	Name	Role
		 Jacqueline Marie Van Audenhove, MS	Principal Investigator

Please verify the list above represents the finalize Personnel for review and signoff?  Yes  No

Cancel - Finalize later Go back to Make changes Save - Start Signoff Routing

# Navigating the IRB Process - iMedRIS

Once you approve and select “save signoff” your submission will be routed to those you designated to signoff. The IRB does not receive your submission until everyone signs off.

IRIS: Review Board Submission 1: X +

https://imedris-training.uthsc.edu/System\_Signoff\_Sheet.jsp?i=1565364855028

Account: Jacqueline M Van Audenhove  
Department: UT GSM - GSMK - Research Center  
Path: Home > project mgmt. > track submission

My Workspaces Project Assistant **Submission Routing Signoff** Back

Save Signoff

Printable Version

Project Title: Training Session Application Form 1  
Submission Reference Number: 707292

Include in PDF Packet	Submission Component Name - Version
Submission Form(s)	
<input type="checkbox"/>	Routing Form for Form 1: Initial Review Submission Form - (Version 1.0)
Application	
<input type="checkbox"/>	UT GSM / UHS Knoxville: IRB Study Application - (Version 1.0)

### GSM PI Responsibilities

In submitting a new study/project application or revision for review and approval by the UTGSM IRB, as principal investigator you agree to assume the following responsibilities and to faithfully execute them in accord with applicable federal regulations for the protection of human subjects and UTGSM IRB policies and procedures:

1. To conduct the research according to the IRB-approved protocol;
2. To obtain and document the informed consent and/or assent of subjects or subjects' legally authorized representatives, using the UTGSM IRB-approved informed consent process and documents, prior to the subjects' participation in any research procedures, unless these requirements have been altered or waived by the IRB;
3. To obtain prior approval from the IRB for any modifications of previously approved research, including modifications to the informed consent process and documents.
4. To ensure that progress reports and requests for continuing review and approval are submitted in the time frame and the manner prescribed by the IRB, but no less than once per year;
5. To provide the IRB with prompt reports of any unanticipated problems involving risks to subjects or others, including adverse events and protocol deviations;
6. To provide the IRB with prompt reports of serious or continuing noncompliance with the federal regulations for the protection of human subjects or the requirements or determinations of the IRB;
7. To notify the IRB regarding the completion of the study/project;
8. To maintain study/project records for the specific lengths of time denoted in the IRB's "Responsibilities of Investigators" policy regarding all records, consent forms, drug study records, and device study records;
9. To assure that all collaborating investigators and other key research personnel involved in the research study/project are fully informed regarding: (a) the study/project procedures; (b) informed consent requirements; (c) the potential adverse events associated with study/project participation and the steps necessary to minimize potential risks; (d) reporting requirements for unanticipated problems; and (e) data collection and record-keeping requirements;
10. To assure that all key research personnel personally complete required training regarding the protection of human subjects prior to their initiation of study/project activities;
11. To disclose to the IRB all conflicts of interest as defined in institutional policy that may relate to the conduct of the research; and
12. To permit inspection and audit of all records related to the conduct of the study/project by authorized representatives of the IRB and departments or agencies supporting or conducting the research.

Jacqueline M Van Audenhove as Principal Investigator  
do you Approve or Deny this submission?  Approve  Deny

This form requires your electronic signature.  
Please enter your User ID & Password:

User ID: jvanaude  
Password: [REDACTED]

Save Signoff

# Navigating the IRB Process - iMedRIS

## Reminders: Forms & Routing for signature

- **Form 1 – Initial Submission** – PI, Department Chair, Faculty Advisor (if applicable). No longer require routing to everyone on the study
- **Form 2 – Amendment** – PI or other Investigator
- **Form 3 – Continuing Review** – PI or other investigator
- **Form 4 – Deviations/AEs/Unanticipated Problem** – PI
- **Form 5 -- Change in Personnel** - PI and personnel being added or removed

# Navigating the IRB & Ethics in Research - Website

## IRB Forms and Documents

Case Report  
Not Human Subjects  
Quality Improvement

### Pre-Application

UHS HIPAA Data Collection Preparatory to Research Form  
UTGSM HIPAA Data Collection Preparatory to Research Form

### Submitting an Application to the IRB

To submit applications to the IRB, please follow the link to iMedRIS.

Please note: Completion of the CITI Basic and Refresher Course is required at the time of IRB submission.

### Collaboration Forms:

- Collaboration Form - Nursing
- Collaboration Form - Pathology
- Collaboration Form - Pharmacy
- Collaboration Form - Radiology and Radiology Research Process Form
- Collaboration Form - Simulation Center

### IRB Documents

Glossary of Lay Terms  
Consent Form Template  
Protocol Template  
Notice of Research Template  
Data Sharing - Data Use Agreement (De-identified)  
Data Sharing - Data Use Agreement (Limited Data Set)

<https://gsm.utmck.edu/irb/main.cfm>

## The Institutional Review Board

- › iMedRIS
- › 2021 Deadline and Meeting Dates
- › Forms
- › The IRB Process
- › Fee Schedule
- › Standard Operating Procedures (Current)
- › Standard Operating Procedures (Pre-2018)
- › Contact Us